They already know CVac is safe, it was announced at the NY conference earlier in the year. They don't know whether CVac is approvable, or how efficacious it might be. So they are going to to the CANVAS trial. They would not be gearing up for the CANVAS trial if there were safety concerns that came out of the PII trial. But in the absense of safety concerns, they will run with a CANVAS trial.
Hence we are seeing the company scale up for a PIII trial.
It is not becuase they are privy to confidential information that is telling them CVac is spectacular. Back to my original point - they would have to disclose that!
increased liquidity? the stock has plenty of liquidity, who you kidding? for a market cap of roughly $100m, it has no substantial shareholders, nor does it have any liquidity problems.
So come october we will see positive safety data - but its not news, because neil already blurted it out in NY. so it shouldn't actually move the shareprice, because everyone is expecting it. So is the ICS data on 6 patients.
the only thing that might move the shareprice is the austrlaian punters who are disallusioned. your best news is reading this thread and realising there are still a lot of misguided investors who might buy in october because they think its a blockbuster, when in reality noone will know.
PRR Price at posting:
9.8¢ Sentiment: LT Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)